MRI-targeted prostate biopsy: a review of technique and results

Robertson, Nicola; Emberton, Mark; Moore, Caroline M.

doi:10.1038/nrurol.2013.196

Cited by 46 publications

(34 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have indicated increased overall diagnostic accuracy for a multiparametric approach, defined as the combination of one structural and at least two functional MRI techniques providing morphological tissue information with T2-weighted MRI (T2W-MRI) and functional tissue information, such as tissue perfusion with dynamic contrast-enhanced MRI (DCE-MRI), or restriction of water solubility with diffusion-weighted imaging (DWI) [4]. …”

Section: Introductionmentioning

confidence: 99%

Multiparametric Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Targeted Biopsy of the Prostate: Preliminary Results of a Prospective Single-Centre Study

Junker

Schäfer²,

Heidegger³

et al. 2015

Urol Int

View full text Add to dashboard Cite

Purpose: To evaluate multiparametric magnetic resonance imaging/transrectal ultrasound (mpMRI/TRUS) fusion targeted biopsy (TB) of the prostate for prostate cancer (PCa) diagnosis. Patients and Methods: From April 2013 to January 2014, 53 men were included in this prospective single-centre study. The degree of PCa suspicion from mpMRI findings was classified according to the PI-RADS scoring system. Of these, 50 patients underwent both an mpMRI/TRUS fusion TB and a 10-core systematic biopsy (SB) of the prostate and were eligible for analysis. Results: 225 targeted and 500 systematic cores were included in this study. PCa was histologically confirmed in 52.0% of patients (26/50), whereas TB revealed PCa in 46.0% (23/50) and SB in 36.0% (18/50). TB identified PCa in 16.0% of all patients (8/50) that were missed by SB. All told, the targeted core was 2.8 times more likely to be PCa-positive than the systematic core (29.3 vs. 10.4%). Conclusions: mpMRI/TRUS fusion TB of the prostate is safe, practicable and may improve PCa diagnosis using fewer biopsy cores compared to SB.

show abstract

Section: Introductionmentioning

confidence: 99%

Multiparametric Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Targeted Biopsy of the Prostate: Preliminary Results of a Prospective Single-Centre Study

Junker

Schäfer²,

Heidegger³

et al. 2015

Urol Int

View full text Add to dashboard Cite

show abstract

“…These have been reviewed in several recent meta-analyses (13)(14)(15)(16). In essence, there are six configurations from which to choose: The navigation or guidance method can be transrectal US or MR imaging, samples can be taken either in the bore or outside the magnet, and the access route can be either transrectal or transperineal.…”

Section: Implication For Patient Carementioning

confidence: 99%

Transperineal In-Bore 3-T MR Imaging–guided Prostate Biopsy: A Prospective Clinical Observational Study

Penzkofer¹,

Tuncalı²,

Fedorov³

et al. 2015

Radiology

View full text Add to dashboard Cite

The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.q RSNA, 2014 Purpose:To determine the detection rate, clinical relevance, Gleason grade, and location of prostate cancer (PCa) diagnosed with and the safety of an in-bore transperineal 3-T magnetic resonance (MR) imaging-guided prostate biopsy in a clinically heterogeneous patient population. Materials and Methods:This prospective retrospectively analyzed study was HIPAA compliant and institutional review board approved, and informed consent was obtained. Eighty-seven men (mean age, 66.2 years 6 6.9) underwent multiparametric endorectal prostate MR imaging at 3 T and transperineal MR imaging-guided biopsy. Three subgroups of patients with at least one lesion suspicious for cancer were included: men with no prior PCa diagnosis, men with PCa who were undergoing active surveillance, and men with treated PCa and suspected recurrence. Exclusion criteria were prior prostatectomy and/or contraindication to 3-T MR imaging. The transperineal MR imaging-guided biopsy was performed in a 70-cm wide-bore 3-T device. Overall patient biopsy outcomes, cancer detection rates, Gleason grade, and location for each subgroup were evaluated and statistically compared by using x 2 and one-way analysis of variance followed by Tukey honestly significant difference post hoc comparisons. Results:Ninety biopsy procedures were performed with no serious adverse events, with a mean of 3.7 targets sampled per gland. Cancer was detected in 51 (56.7%) men: 48.1% (25 of 52) with no prior PCa, 61.5% (eight of 13) under active surveillance, and 72.0% (18 of 25) in whom recurrence was suspected. Gleason pattern 4 or higher was diagnosed in 78.1% (25 of 32) in the no prior PCa and active surveillance groups. Gleason scores were not assigned in the suspected recurrence group. MR targets located in the anterior prostate had the highest cancer yield (40 of 64, 62.5%) compared with those for the other parts of the prostate (P , .001). Conclusion:In-bore 3-T transperineal MR imaging-guided biopsy, with a mean of 3.7 targets per gland, allowed detection of many clinically relevant cancers, many of which were located anteriorly.q RSNA, 2014

show abstract

“…Moderne bildgebende Techniken haben mittlerweile bewiesen, dass sie relativ zuverlässig signifikante Prostatakarzinome nachweisen können [4]. Daher kommt der Visualisierung des Prostatakarzinoms eine wichtige Rolle zu.…”

Section: Hintergrundunclassified